Evidence map›Paper›PMID 33760403›Full record

ArticleESC heart failure2021

Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction.

Mitsutaka Nakashima, Satoru Sakuragi, Toru Miyoshi, Shin Takayama, Tatsuto Kawaguchi, Nobuhisa Kodera, Hiroaki Akai, Yuji Koide, Hiroaki Otsuka, Tadashi Wada and 4 more

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Cardiohepatic Axis in Metabolic Disease: Liver to Heart.JACC. Basic to translational science · 2025
    Review
  13. Article
  14. Article
  15. Fibrosis-4 index is closely associated with future development of hypertension in the Japanese general population.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mitsutaka NakashimaDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Pharmaceutical Sciences Medicine, Dentistry, Okayama, Japan.
Satoru SakuragiDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Toru MiyoshiDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Pharmaceutical Sciences Medicine, Dentistry, Okayama, Japan.
Shin TakayamaDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Tatsuto KawaguchiDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Nobuhisa KoderaDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Hiroaki AkaiDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Yuji KoideDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Hiroaki OtsukaDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Tadashi WadaDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Kenji KawamotoDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Machiko TanakayaDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Yusuke KatayamaDepartment of Cardiovascular Medicine, National Hospital Organization Iwakuni Clinical Center, 1-1-1 Atagomachi, Iwakuni, Yamaguchi, 740-8510, Japan.
Hiroshi ItoDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Pharmaceutical Sciences Medicine, Dentistry, Okayama, Japan.
Iwakuni Medical Center · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsFibrosis-4 index (FIB-4 index), calculated by age, aspartate aminotransferase, alanine aminotransferase, and platelet count, is a simple marker to evaluate liver fibrosis and is associated with right-sided heart failure. However, the clinical relevance of FIB-4 in patients with heart failure with preserved ejection fraction (HFpEF) remains unclear. We investigated the prognostic implication of the FIB-4 index regarding right ventricular dysfunction in patients with HFpEF. METHODS AND

resultsThis prospective study included 116 consecutive HFpEF patients (mean age 79 years, 43% male) hospitalized with acute decompensated heart failure. We evaluated the association of the FIB-4 index with right ventricular function determined by tricuspid annular plane systolic excursion (TAPSE) and tricuspid lateral annular systolic velocity (S') before discharge. Cox regression analysis was performed to evaluate the association between the FIB-4 index and major adverse cardiovascular events (MACE) defined as the composite of cardiovascular death, readmission for heart failure, nonfatal myocardial infarction, and nonfatal stroke. FIB-4 index before discharge was significantly lower than that at admission (2.62 [1.92-3.46] and 3.03 [2.05-4.67], median [interquartile range], P < 0.001). Left ventricular ejection fraction, TAPSE, and S' before discharge were 62.7 (55.9-68.6) %, 17.5 ± 4.6 mm (mean ± standard deviation), and 10.0 (8.0-12.0) cm/s, respectively. In multiple linear regression analysis, the FIB-4 index before discharge was inversely correlated with TAPSE (β minus;0.244, P = 0.014) and S' (β -0.266, P = 0.009). During a median follow-up of 736 days, 37 MACE occurred. Multivariate Cox regression analysis revealed that a high FIB-4 index before discharge (per 1 point) was a significant predictor of MACE (hazard ratio 1.270, 95% confidence interval 1.052-1.532) after adjustment for male, serum creatinine, and haemoglobin. Receiver operating characteristic analysis indicated that the optimal cut-off value of FIB-4 index before discharge to predict MACE was 3.11. Kaplan-Meier survival analysis showed that patients with a FIB-4 index before discharge ≥3.11 had a significantly poorer prognosis than patients with FIB-4 index before discharge <3.11 (P = 0.029). Patients with an FIB-4 index ≥3.11 had a 2.202-fold (95% confidence interval 1.110-4.368) increased risk of MACE compared with those with an FIB-4 index <3.11 after adjustment for male, serum creatinine, and haemoglobin.

conclusionsAn increase in the FIB-4 index was associated with right ventricular dysfunction and a higher risk of future MACE in patients with HFpEF.

Indexed as

Heart FailureVentricular Function, RightAgedFemaleFibrosisHumansMalePrognosisProspective StudiesStroke VolumeVentricular Function, LeftFibrosis-4 indexHFpEFLiver fibrosisMajor adverse cardiac eventsRight ventricular function

Identifiers

PMID33760403
PMCPMC8120399
OpenAlexW3137458211

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.